Skip to content
cell therapy
-
Kincell Bio and Cellipont Bioservices merge to create Kincellis Advanced Therapies
The new company combines Kincell’s expertise in immune-cell technologies with Cellipont’s experience in stem cells, induced pluripotent stem cells (iPSCs), mesenchymal stromal cells (MSCs), dendritic cells, exosomes and emerging messenger RNA (mRNA) technologies.
-
Cellular Intelligence acquires Novo Nordisk’s Parkinson’s Cell Therapy Program in AI-driven deal
Cellular Intelligence plans to continue the clinical development of the Parkinson’s therapy using its proprietary artificial intelligence platform, which is designed to optimize cell therapy manufacturing and accelerate development timelines.